HPV vaccine MedImmune/GlaxoSmithKline.
MedImmune, in collaboration with GlaxoSmithKline, is developing a vaccine consisting of self-assembling, virus-like particles for the prevention of human papillomavirus (HPV) infection of the genital tract and associated cervical cancer. The vaccine candidates include the prototype vaccine, MEDI-501 (a vaccine directed against HPV-11), MEDI-503 (directed against HPV-16) and MEDI-504 (directed against HPV-18). Following phase I studies, the HPV-16 and HPV-18 components were combined into a multivalent vaccine for subsequent trials; this vaccine is known as MEDI-517. Phase II trials of MEDI-517 were initiated by January 2000 and are currently ongoing.
Billich
Andreas
A
Novartis Research Institute, PO Box 80, Brunner Strasse 59, 1235 Vienna, Austria. andreas.billich@pharma.novartis.com
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D013329:Structure-Activity Relationship; D014765:Viral Vaccines / Q000009:adverse effects / Q000138:chemical synthesis / Q000276:immunology*
D053918:Papillomavirus Vaccines; D014765:Viral Vaccines